Does plasma B-type natriuretic peptide reduction predict long-term response to levosimendan therapy in acutely decompensated chronic heart failure?
Treatment-induced BNP reduction is an independent predictor of 6-month outcome following levosimendan therapy in ADHF.
The findings showed that LDH patients had higher baPWV levels. In addition, reduced physical activity was a risk factor contributing to increased baPWV. Further studies are warranted to determine the role of baPWV in LDH.